Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2316

2.
3.

Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.

Vermeulen M, Lelie N, Sykes W, Crookes R, Swanevelder J, Gaggia L, Le Roux M, Kuun E, Gulube S, Reddy R.

Transfusion. 2009 Jun;49(6):1115-25. doi: 10.1111/j.1537-2995.2009.02110.x. Epub 2009 Feb 27.

PMID:
19309474
4.

A multi-Chinese blood center study testing serologic-negative donor samples for hepatitis C virus and human immunodeficiency virus with nucleic acid testing.

Shan H, Ren FR, Zhao HY, Zhang YZ, Wen GX, Yao FZ, Gao GJ, Yan LX, Jiang CF, Bai XH, Tiemuer MH, Tu YQ, Zhu FM, Zheng YR, Cui L, Liu CL, Gong XY, Lv QS, Zheng P, Ziermann R, Ness P, Wang JX.

Transfusion. 2007 Nov;47(11):2011-6.

PMID:
17958529
5.

Evaluation of a multiplex human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus nucleic acid testing assay to detect viremic blood donors in northern Thailand.

Nantachit N, Thaikruea L, Thongsawat S, Leetrakool N, Fongsatikul L, Sompan P, Fong YL, Nichols D, Ziermann R, Ness P, Nelson KE.

Transfusion. 2007 Oct;47(10):1803-8.

PMID:
17880604
6.

Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.

Jarvis LM, Dow BC, Cleland A, Davidson F, Lycett C, Morris K, Webb B, Jordan A, Petrik J.

Vox Sang. 2005 Oct;89(3):128-34.

PMID:
16146504
7.

[Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].

Pillonel J, Laperche S; Groupe "Agents Transmissibles par Transfusion" de la Société française de transfusion sanguine.; Etablissement français du sang.; Centre de transfusion sanguine des armées..

Transfus Clin Biol. 2004 Apr;11(2):81-6. French.

PMID:
15120104
8.

Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.

Velati C, Romanò L, Fomiatti L, Baruffi L, Zanetti AR; SIMTI Research Group..

Transfusion. 2008 Oct;48(10):2205-13. doi: 10.1111/j.1537-2995.2008.01813.x. Epub 2008 Jul 8.

PMID:
18631163
9.

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

Weusten JJ, van Drimmelen HA, Lelie PN.

Transfusion. 2002 May;42(5):537-48.

PMID:
12084161
10.

Acute hepatitis C virus seroconversion in a Scottish blood donor: HCV antigen is not comparable with HCV nucleic acid amplification technology screening.

Dow BC, Munro H, Buchanan I, Ferguson K, Davidson F, Lycett C, Jarvis M, Cleland A, Petrik J, Lumley S, MacLean A.

Vox Sang. 2004 Jan;86(1):15-20.

PMID:
14984555
11.

Prevalence, incidence, and residual risk of human immunodeficiency virus among community and replacement first-time blood donors in São Paulo, Brazil.

Barreto CC, Sabino EC, Gonçalez TT, Laycock ME, Pappalardo BL, Salles NA, Wright DJ, Chamone DF, Busch MP.

Transfusion. 2005 Nov;45(11):1709-14.

PMID:
16271094
12.

A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.

Li L, Chen PJ, Chen MH, Chak KF, Lin KS, Tsai SJ.

Transfusion. 2008 Jun;48(6):1198-206. doi: 10.1111/j.1537-2995.2008.01672.x. Epub 2008 Apr 14.

PMID:
18422856
13.

High throughput screening of 16 million serologically negative blood donors for hepatitis B virus, hepatitis C virus and human immunodeficiency virus type-1 by nucleic acid amplification testing with specific and sensitive multiplex reagent in Japan.

Mine H, Emura H, Miyamoto M, Tomono T, Minegishi K, Murokawa H, Yamanaka R, Yoshikawa A, Nishioka K; Japanese Red Cross NAT Research Group..

J Virol Methods. 2003 Sep;112(1-2):145-51.

PMID:
12951223
14.

Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe.

Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E.

Transfusion. 2002 Jul;42(7):862-8.

PMID:
12375658
15.

A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.

Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH; NHLBI-REDS NAT Study Group..

Transfusion. 2005 Feb;45(2):254-64.

PMID:
15660836
16.

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.

Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP; National Heart, Lung, and Blood Institute Nucleic Acid Test Study Group..

N Engl J Med. 2004 Aug 19;351(8):760-8.

17.

Nucleic acid technology screening of Australian blood donors for hepatitis C and human immunodeficiency virus-1 RNA: comparison of two high-throughput testing strategies.

Mison L, Seed CR, Margaritis AR, Hyland C; Australian Red Cross Blood Service Nucleic Acid Technology Study Group..

Vox Sang. 2003 Jan;84(1):11-9.

PMID:
12542729
18.

Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.

Shang G, Seed CR, Wang F, Nie D, Farrugia A.

Transfusion. 2007 Mar;47(3):529-39.

PMID:
17319836
19.

Multicenter evaluation of individual donor nucleic acid testing (NAT) for simultaneous detection of human immunodeficiency virus -1 & hepatitis B & C viruses in Indian blood donors.

Makroo RN, Choudhury N, Jagannathan L, Parihar-Malhotra M, Raina V, Chaudhary RK, Marwaha N, Bhatia NK, Ganguly AK.

Indian J Med Res. 2008 Feb;127(2):140-7.

PMID:
18403791
20.

Two HBV DNA+/HBsAg- blood donors identified by HBV NAT in Shenzhen, China.

Shang G, Yan Y, Yang B, Shao C, Wang F, Li Q, Seed CR.

Transfus Apher Sci. 2009 Aug;41(1):3-7. doi: 10.1016/j.transci.2009.05.001. Epub 2009 May 31.

PMID:
19487161

Supplemental Content

Support Center